Epanova

DRUG4 trials

Sponsors

Tillotts Pharma AG, AstraZeneca

Conditions

Crohn's DiseaseHealthy SubjectsHypertriglyceridemiaSevere Hypertriglyceridemia

Phase 1

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

CompletedNCT02189252

AstraZenecaSevere Hypertriglyceridemia

Start: 2014-10-31End: 2015-07-31Updated: 2016-06-20

A Ph 1 Study of Epanova® in Healthy Chineses

CompletedNCT03574142

AstraZenecaHealthy Subjects

Start: 2018-06-04End: 2018-06-27Updated: 2018-07-05

Phase 3

EPANOVA in Crohn's Disease, Study 1

CompletedNCT00613197

Tillotts Pharma AGCrohn's Disease

Start: 2003-01-31End: 2006-08-31Updated: 2013-04-04

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

CompletedNCT02009865

AstraZenecaHypertriglyceridemia

Start: 2013-12-16End: 2014-12-23Updated: 2019-09-10

Related Papers

Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.

2020-05-305 citations

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.

2008-04-01169 citations